Rana Ali, MD
Pulmonary Disease · Ocean, NJNPI 1619083177
Payments from drug & device makers
Across 545 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Philips North America LLC$858
- Harmony Biosciences LLC$699
- Inspire Medical Systems, Inc.$673
- Jazz Pharmaceuticals Inc.$468
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,88797%
- Education$3213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 100 | $2,058 |
| GSK | 99 | $1,170 |
| Philips North America LLC | 75 | $858 |
| Harmony Biosciences LLC | 30 | $699 |
| Inspire Medical Systems, Inc. | 17 | $673 |
| Jazz Pharmaceuticals Inc. | 24 | $468 |
| Sanofi | 28 | $467 |
| Avadel CNS Pharmaceuticals, LLC | 25 | $465 |
| Mylan Specialty L.p. | 23 | $366 |
| Amgen(2 entities) | 22 | $308 |
| Regeneron Healthcare Solutions, Inc. | 17 | $281 |
| Boehringer Ingelheim | 15 | $213 |
| Viatris Specialty LLC | 14 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $131 |
| Actelion Pharmaceuticals US, Inc. | 4 | $123 |
| Grifols USA, LLC | 6 | $110 |
| Baxter Healthcare | 5 | $95 |
| United Therapeutics Corporation | 5 | $80 |
| Sanofi-aventis U.S. LLC | 1 | $58 |
| Sunovion Pharmaceuticals Inc. | 5 | $51 |
| Pulmonx Corporation | 1 | $41 |
| Electromed, Inc. | 3 | $35 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| Merck | 2 | $30 |
| Insmed, Inc. | 2 | $29 |
| Covis Pharma GmbH | 2 | $27 |
| Lilly USA, LLC | 1 | $21 |
| Verona Pharma, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Bayer | 1 | $14 |
| Optinose US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,208 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 53 | $729,660 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 51 | $529,732 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 283 | $259,142 |
| Dupixent PenDupilumab | 50 | $192,435 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 182 | $148,108 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $144,882 |
| WakixPitolisant Hcl | 18 | $144,660 |
| OfevNintedanib Esylate | 14 | $119,140 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 206 | $115,263 |
| Breo ElliptaFluticasone/Vilanterol | 217 | $99,713 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $90,581 |
| Spiriva RespimatTiotropium Bromide | 101 | $72,237 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 62 | $29,564 |
| Advair HfaFluticasone Propion/Salmeterol | 48 | $20,179 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $20,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C, Gamunex-C | $110 | $620,31368 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,170 | $487,564737 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $213 | $220,940177 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,058 | $168,154251 claims |
| Harmony Biosciences LLCWakix | $699 | $144,66018 claims |
| MerckDulera | $30 | $9,58423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Ocean
- James CosentinoOcean$18K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.